Competitor Analysis: Emerging Diabetes Drugs

Date: April 22, 2011
Pages: 104
Price:
US$ 870.00
License [?]:
Publisher: La Merie Publishing
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C482A7D2124EN
Leaflet:

Download PDF Leaflet

Competitor Analysis: Emerging Diabetes Drugs
Product description

The present Competitive Intelligence Report about Emerging Diabetes Drugs provides a competitor evaluation in the field of novel molecules against a series of novel targets being developed for treatment of type 1 or 2 diabetes as of April 2011. Pharmacologic approaches include SGLT inhibitors, glucokinase activators, 11beta-HSD1 inhibitors and many others. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of novel molecules for treatment of type 1 and 2 diabetes. In addition, the report lists company-specific R&D pipelines of emerging diabetes drugs in R&D. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

Index
  • Sodium-Dependent Glucose Co-Transporter (SGLT) Inhibitors
  • 11beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors
  • Glucokinase Activators (GKA)
  • Adenosine Monophosphate Activated Protein Kinase (AMPK) Agonists
  • Sirtuin (SIRT) Activators
  • Protein tyrosine Phosphatase-1B (PTP-1B) Inhibitors
  • Glucagon Receptor (GCGR) Antagonists
  • Glucocorticoid Receptor (GCGR) Antagonists
  • Novel Insulin Sensitizers
  • G-Protein Coupled Receptor 119 (GPR119) Agonists
  • Other Drugs Augmenting GLP-1 Secretion: GPR40, GR120 & TGR5 Agonists
  • Other Glucometabolic Approaches
  • Acyl-CoA:Diacylglycerol Acyltransferase1 (DGAT1) Inhibitors
  • Other Metabolic Approaches
  • FGF-21-Receptor Agonists
  • Anti-Inflammatory Approaches
  • Induction of Immune Tolerance
  • Pancreatic Beta Cell Protection & Regeneration
  • Pancreatic Islet Cell Transplantation
  • Various Antidiabetic Approaches

Corporate Emerging Diabetes Drugs R&D Pipelines
  • 7TM Pharma
  • Abbott
  • AdiStem
  • Advinus Therapeutics
  • Alize Pharma
  • ALLOZYNE
  • Ambrx
  • Amgen
  • Amylin Pharmaceuticals
  • Andromeda
  • Arena Pharmaceuticals
  • Array BioPharma
  • Astellas Pharma
  • AstraZeneca
  • Bayhill Therapeutics
  • Betagenon
  • BHV Pharma
  • Biocon
  • Boehringer Ingelheim
  • Bristol-Myers Squibb (BMS)
  • Catabasis Pharmaceuticals
  • Cellonis Biotechnologies
  • ChemoCentryx
  • Columbia University Medical Center
  • Connexios Life Sciences
  • Cortendo
  • CureDM Group
  • Cyclacel
  • Cytos Biotechnology
  • Daiichi Sankyo
  • Dainippon Sumitomo Pharma
  • Debiopharm
  • DiaKine Therapeutics
  • Diamedica
  • Diamyd Medical
  • Eli Lilly
  • Ensemble Discovery
  • Evotec
  • Exsulin
  • Forest Laboratories
  • Genzyme
  • Geron Corp
  • GlaxoSmithKline (GSK)
  • Helsinn
  • High Point Pharmaceuticals
  • Immunocore
  • Incyte
  • Inovio
  • Intercept Pharmaceuticals
  • Ipsen
  • ISIS Pharmaceuticals
  • Japan Tobacco
  • Johnson & Johnson (J&J)
  • Kalypsys
  • Karo Bio
  • Kotobuki
  • Les Laboratoires Servier (Servier)
  • Lexicon Pharmaceuticals
  • LG Life Science
  • Ligand Pharmaceuticals
  • Living Cell Technologies (LCT)
  • MacroGenics
  • MedImmune
  • Melior Discovery
  • Mesoblast
  • Metabolex
  • Merck & Co.
  • Mercury Therapeutics
  • MicroIslet
  • Mitsubishi Tanabe Pharma
  • Neurocrine Biosciences
  • National Institutes of Health (NIH)
  • Novartis
  • NovImmune
  • Omni Bio Pharmaceutical
  • Ortho-McNeil-Janssen Pharmaceuticals (OMJPI)
  • Ortho McNeil (J&J)
  • Osiris therapeutics
  • Pfizer
  • PharmaFrontier
  • Pinnacle
  • Piramal Life Sciences
  • Poxel
  • Rigel Pharmaceuticals
  • Roche
  • Sanofi-Aventis
  • S2 Therapeutics
  • Santarus
  • Sanwa Kagaku Kenkyusho
  • Sirona Biochem
  • Takeda Pharmaceutical
  • Targacept
  • Teva Pharmacetical Industries
  • Theracos
  • Tolera Therapeutics
  • Tolerx
  • TransTech Pharma
  • VeroScience
  • Versartis
  • VIA Pharmaceuticals
  • ViaCyte
  • Vitae Pharmaceuticals
  • Wellstat Therapeutics
  • XOMA
  • Yuhan Co.
  • Zydus Cadila

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Skip to top


BRIC Diabetes Drugs Market US$ 5,650.00 Apr, 2010 · 118 pages
Competitor Analysis: Targeted Therapy of Diabetes US$ 1,735.00 Apr, 2011 · 114 pages
World Diabetes Drug Market 2011-2021 US$ 2,325.00 Mar, 2011 · 224 pages

Ask Your Question

Competitor Analysis: Emerging Diabetes Drugs
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: